While Parkinson’s Disease (PD) is widely recognized for its motor symptoms, like tremors, stiffness, and slowed movement, nearly half of all patients also experience neuropsychiatric symptoms, including anxiety, depression, and psychosis. A new research initiative led by Binghamton University, in collaboration with the Barrow Neurological Institute and the University of Illinois at Chicago, is diving deeper into the biological roots of these symptoms.
The team is investigating how serotonin-producing neurons, which can release dopamine when exposed to L-DOPA (a common PD treatment), may contribute to these psychiatric effects. This uncontrolled dopamine release may lead to aberrant neuroplasticity, potentially worsening anxiety and other symptoms.
Using advanced techniques in animal models, researchers have already shown that specific cellular changes can increase anxiety levels. Their long-term goal is to identify repurposable medications that target serotonin dysfunction, potentially offering new hope for managing the non-motor symptoms of PD.
This research could significantly improve the quality of life for PD patients, especially veterans, who are disproportionately affected by the disease.